Independent Clinical Trial Results
University of Houston College of Pharmacy
Peer-Reviewed: Conclusion: The findings support the routine use of ISDD during blood culture collection in the ED as a cost-beneficial strategy to reduce the clinical and economic impact of blood culture contamination in terms of microbiology, pharmacy and wider indirect hospital impact.
Study results show a single false positive blood culture event results in an additional $4,739 in hospital costs. The study concluded that the routine implementation of Steripath ISDD in the ED was a cost -beneficial compared to conventional blood culture collection methods. Depending on a facility’s baseline contamination rate (ranging from 2-8 percent), hospitals can expect a cost savings between $83 and $367 per blood culture following adoption of Steripath. These findings support the routine use of ISDD during blood culture collection in the ED as a cost-beneficial strategy to reduce the clinical and economic impact of blood culture contamination in terms of microbiology, pharmacy and wider indirect hospital impact.
University of Nebraska Medical Center
Peer-Reviewed: Conclusion: Use of the ISDD was associated with a significant decrease in blood culture contamination in patients undergoing blood cultures in an Emergency Department setting.
Clinical Infectious Diseases journal has published study results from the University of Nebraska Medical Center led by Dr. Mark E. Rupp, Professor and Chief of the UNMC Division of Infectious Diseases and Medical Director of the Department of Infection Control and Epidemiology at Nebraska Medicine, UNMC’s hospital partner. The study validates the performance of the Steripath blood collection system to reduce blood culture contamination to 0.2% (P=0.001). This represented a 92% reduction compared to a pre-intervention rate of 2.6% and 88% reduction compared to the phlebotomist control group intervention rate of 1.8%. Post hoc analysis found contamination rates increased 12 fold to 2.8% without the use of Steripath. Researcher calculated the study institution would save $1.8M per year with Steripath
Peer-Reviewed: Conclusion: This unique collection system can reduce the risk of blood culture contamination significantly and is designed to augment, rather than replace, the standard phlebotomy protocol already in use in most health care settings.
The study results show that the Steripath blood culture collection and contamination prevention system reduced blood culture contamination to a sustained 0.6% (P=0.0001) across 4 Emergency Departments over a 7-month period. This represented a 82.8% reduction compared to a pre-intervention rate of 3.52%. Post hoc analysis found that BCC rate reduction was comparable across all 4 facilities, with each Emergency Department achieving a sustained sub-0.75% rate of contamination after adoption of the device. During the observational period of this study, projected cost savings exceeds $641,000 and prevented approximately 184 patients from being exposed to the risks associated with a false positive blood culture.
Rush University Medical Center
Conclusion: The use of the SP device in the ED over a 3-month period significantly reduced the rate of blood culture contamination from 4.3% to 0.6% while the rates of true bacteremia remain unchanged. The SP device represents a simple and effective method for reducing blood culture contamination.
Prospective study results showing an 86% reduction in blood culture contamination, 4.3% when using standard aseptic technique vs. 0.6% utilizing Steripath. Steripath represents a simple and effective method for reducing blood culture contamination.
San Antonio Military Medical Center
Conclusion: Data indicates use of SteriPath significantly reduces contamination rates. Approximately $5,000 per false positive result. BAMC has saved over $235,000 since September 2015 by utilizing SteriPath in Emergency Department.
The study results show a 92% reduction in blood culture contamination, 7.7% using standard collection method vs. 0.6% utilizing Steripath, and a projected costs savings of $235,000 in five months.
San Antonio Military Medical Center
Conclusion: Empiric vancomycin usage decreased after implementation of a molecular detection assay and diversion blood collection methods. While both pre and post-analytic methods decrease vancomycin use, greater de-escalation was best achieved through a combination of methods.
Retrospective study results showing a 37% decrease in Vancomycin days of therapy attributed to Steripath.
Conclusion: Use of the ISDD device led to a significant decrease in the BCC rate in all groups that participated in the trial: ED, ICU, and phlebotomy team. The contamination rate for specimens collected with the ISDD was 0.76%, which is a 73% reduction compared to the historical rate of 2.8%.
Prospective study results showing an 75% reduction in blood culture contamination, 3.0% when using standard collection method vs. 0.8% utilizing Steripath. Results led the hospital to adopt Steripath as standard practice hospital-wide.
Medical University of South Carolina
Conclusion: ISDD use decreased FPBCs below 1% in a busy adult ED, well below the national benchmark of 3%, and the reduction in FPBC has been sustained for 20 months. Reducing FPBCs has led to reduced related costs and more efficient use of staff time, while helping to comply with national/international efforts to improve antibiotic stewardship and patient safety.
Prospective study results show Steripath drove a nearly four-fold reduction in false-positive blood culture rate compared to the non-Steripath rate during the same time period. Estimated cost savings to the institution of $744,955 for the study period if there were 100% compliance. Compliance rate impacted by uncooperative or "difficult to stick" patients.
Medical University of South Carolina
Conclusion: The SteriPath device successfully reduced the number of FPBC over the 8-month trial period (average of 0.57% with vs 4.17% without). We suspect that vendor training lead to an increased focus on proper BC collection technique by all nursing personnel, resulting in a 50% decrease in FPBC rate for all adult ED BC (4.6% in FY2015 to 2.3% in FY2016).
Prospective study results showing an 86% reduction in blood culture contamination, 4.2% when using standard collection method vs. 0.6% utilizing Steripath. Results drove expansion of Steripath use to a second, separate adult ED, and the ICU.
Michael E. DeBakey VA Medical Center - Houston
Conclusion: ER ISDD use resulted in a 83% decrease compared to UC (P=.01). ER study supported Leadership decision to implement the ISDD hospital-wide. High use areas [Acute care, Medical, Surgical, Prime Care, Phlebotomy and ER] began ISDD use October, 2017. As utilization of ISDD has increased, and with the conversion to the second generation ISDD, hospital-wide BCC rates have continued to decrease.
Prospective study results showing an 83% reduction in blood culture contamination when using standard collection method vs. utilizing Steripath. The study supported Leadership decision to implement Steripath ISDD hospital-wide.
VA - North Texas Health Care System
Conclusion: A post-Steripath adoption blended (combined Steripath and standard method results) blood culture contamination rate of 1.7% at 50% compliance compared to a pre-Steripath implementation of 5.3%, representing a 69% reduction. Steripath enabled a 45% reduction in blood culture collection steps and an estimated savings of $332,500 over a five month period.
Poster presented as a Green Belt Project 2016, study results showed a post-Steripath adoption blended (combined Steripath and standard method results) blood culture contamination rate of 1.7% at 50% compliance compared to a pre-Steripath implementation of 5.3%, representing a 69% reduction. Steripath enabled a 45% reduction in blood culture collection steps and an estimated savings of $332,500 over a five month period.
The evidence speaks for itself.
Let us share more.